Q2 EPS Estimates for Pyxis Oncology Lowered by HC Wainwright

Pyxis Oncology, Inc. (NASDAQ:PYXS) – Analysts at HC Wainwright dropped their Q2 2026 earnings estimates for Pyxis Oncology in a report released on Friday, May 15th. HC Wainwright analyst S. Ramakanth now anticipates that the company will earn ($0.38) per share for the quarter, down from their prior forecast of ($0.36). HC Wainwright currently has a “Buy” rating and a $7.00 target price on the stock. The consensus estimate for Pyxis Oncology’s current full-year earnings is ($1.23) per share. HC Wainwright also issued estimates for Pyxis Oncology’s Q3 2026 earnings at ($0.25) EPS, Q4 2026 earnings at ($0.23) EPS, FY2026 earnings at ($0.99) EPS, Q1 2027 earnings at ($0.19) EPS, Q2 2027 earnings at ($0.19) EPS, Q3 2027 earnings at ($0.19) EPS, Q4 2027 earnings at ($0.20) EPS, FY2027 earnings at ($0.78) EPS and FY2028 earnings at ($0.35) EPS.

Other equities research analysts have also recently issued reports about the stock. Wedbush started coverage on shares of Pyxis Oncology in a research report on Tuesday, May 5th. They set an “outperform” rating and a $6.00 price target for the company. Stifel Nicolaus dropped their price objective on shares of Pyxis Oncology from $9.00 to $8.00 and set a “buy” rating for the company in a report on Tuesday, March 24th. Weiss Ratings restated a “sell (d-)” rating on shares of Pyxis Oncology in a report on Thursday, January 22nd. Finally, Wall Street Zen cut shares of Pyxis Oncology from a “hold” rating to a “sell” rating in a report on Saturday. Six research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $6.83.

Pyxis Oncology Trading Down 11.4%

Pyxis Oncology stock opened at $2.02 on Tuesday. Pyxis Oncology has a 12-month low of $0.97 and a 12-month high of $5.55. The stock has a market cap of $126.97 million, a P/E ratio of -1.54 and a beta of 1.43. The company has a 50-day moving average price of $1.73 and a 200 day moving average price of $2.28.

Pyxis Oncology (NASDAQ:PYXS) last released its quarterly earnings results on Thursday, May 14th. The company reported ($0.37) EPS for the quarter, missing the consensus estimate of ($0.35) by ($0.02).

Institutional Trading of Pyxis Oncology

Several institutional investors and hedge funds have recently bought and sold shares of the business. Renaissance Technologies LLC increased its stake in Pyxis Oncology by 26.4% in the 4th quarter. Renaissance Technologies LLC now owns 728,380 shares of the company’s stock valued at $838,000 after buying an additional 152,044 shares during the period. Marshall Wace LLP acquired a new position in Pyxis Oncology in the 4th quarter valued at $448,000. ExodusPoint Capital Management LP acquired a new position in Pyxis Oncology in the 4th quarter valued at $365,000. Velan Capital Investment Management LP increased its stake in Pyxis Oncology by 37.5% in the 3rd quarter. Velan Capital Investment Management LP now owns 55,000 shares of the company’s stock valued at $122,000 after buying an additional 15,000 shares during the period. Finally, Quadrature Capital Ltd acquired a new position in Pyxis Oncology in the 4th quarter valued at $116,000. Hedge funds and other institutional investors own 39.07% of the company’s stock.

About Pyxis Oncology

Pyxis Oncology (NASDAQ: PYXS) is a clinical?stage biotechnology company focused on the discovery and development of targeted oncology therapies. The company’s platform centers on antibody?drug conjugates (ADCs) that deliver potent mitotic inhibitors directly to cancer cells, leveraging novel payloads designed to disrupt cell division. By combining highly specific antibodies with innovative cytotoxic agents, Pyxis Oncology aims to improve therapeutic windows and reduce off?target toxicities common to conventional chemotherapies.

Since its inception, Pyxis Oncology has built a pipeline of early?stage ADC candidates directed against a variety of solid tumor antigens.